Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt

Research output: Contribution to journalArticle

25 Citations (Scopus)
564 Downloads (Pure)

Abstract

Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
Original languageEnglish
Pages (from-to)1-386
Number of pages386
JournalHealth Technology Assessment
Volume17
Issue number29
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Cost-Benefit Analysis
Neoplasm Metastasis
Bone and Bones
Neoplasms
Therapeutics
Denosumab

Cite this

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. / Ford, J; Cummins, E; Sharma, P; Elders, A; Stewart, F; Johnston, R; Royle, P; Jones, R; Mulatero, C; Todd, R; Mowatt, G.

In: Health Technology Assessment, Vol. 17, No. 29, 07.2013, p. 1-386.

Research output: Contribution to journalArticle

Ford, J, Cummins, E, Sharma, P, Elders, A, Stewart, F, Johnston, R, Royle, P, Jones, R, Mulatero, C, Todd, R & Mowatt, G 2013, 'Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours', Health Technology Assessment, vol. 17, no. 29, pp. 1-386. https://doi.org/10.3310/hta17290
Ford, J ; Cummins, E ; Sharma, P ; Elders, A ; Stewart, F ; Johnston, R ; Royle, P ; Jones, R ; Mulatero, C ; Todd, R ; Mowatt, G. / Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. In: Health Technology Assessment. 2013 ; Vol. 17, No. 29. pp. 1-386.
@article{d2eb550a257b4790a1592a33d189795e,
title = "Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours",
abstract = "Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.",
author = "J Ford and E Cummins and P Sharma and A Elders and F Stewart and R Johnston and P Royle and R Jones and C Mulatero and R Todd and G Mowatt",
year = "2013",
month = "7",
doi = "10.3310/hta17290",
language = "English",
volume = "17",
pages = "1--386",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "National Co-ordinating Centre for HTA",
number = "29",

}

TY - JOUR

T1 - Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

AU - Ford, J

AU - Cummins, E

AU - Sharma, P

AU - Elders, A

AU - Stewart, F

AU - Johnston, R

AU - Royle, P

AU - Jones, R

AU - Mulatero, C

AU - Todd, R

AU - Mowatt, G

PY - 2013/7

Y1 - 2013/7

N2 - Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.

AB - Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.

U2 - 10.3310/hta17290

DO - 10.3310/hta17290

M3 - Article

VL - 17

SP - 1

EP - 386

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 29

ER -